TABLE 1.

Serum and distal mucosal antibody responses following mucosal genetic cotransfer of gB DNA plus chemokines^a

Immunization	Serum gB-specific antibody response		Mucosal gB-specific antibody response
	IgG (ng/ml)	IgG2a/IgG1 ratio	Vaginal IgA		Fecal IgA
			gB specific (pg/ml)	% gB IgA	gB specific (ng/ml)	% gB IgA
pCI-neo alone	10 ± 3		18 ± 17		2.1 ± 0.6
gB DNA + pCI-neo	181 ± 67	5.3	160 ± 86	0.01	7.5 ± 4.4	0.04
+ MIP-1α	436 ± 75b	14.6	582 ± 152b	0.04	11.2 ± 3.7	0.08
+ MIP-1β	142 ± 92	4.9	141 ± 74	0.01	7.5 ± 3.7	0.04
+ MIP-2	321 ± 158	18.5	100 ± 75	0.01	6.0 ± 3.2	0.05
+ MCP-1	538 ± 124b	2.6	457 ± 88b	0.03	8.0 ± 2.2	0.06
HSV i.n.	20,982 ± 2,755b	117.0	5,666 ± 752b	0.56	23.0 ± 3.8b	0.16

^aBALB/c mice (seven mice per group) were coimmunized i.n. with 100 μg of gB DNA plus 200 μg of chemokine DNA. The immunization was repeated three times at 5-day intervals. Ten days following the last immunization, serum samples, vaginal lavage fluid, and fecal samples were collected and analyzed individually. The levels of gB-specific antibody were measured by ELISA. Vaginal IgA responses were measured from pooled samples, and fecal samples were resuspended at 100 mg/ml in PBS–0.1% sodium azide. Individual samples were tested for gB-specific as well as total IgA responses. % gB IgA ([gB-specific IgA/total IgA] × 100) was determined from fecal and vaginal samples of mice immunized with HSV and gB DNA. 

^bSignificantly different from values obtained for mice coimmunized i.n. with gB DNA plus control vector pCI-neo (P < 0.05).